FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175962993> ?p ?o ?g. }

• W3175962993 abstract "Early and effective glycemic control can prevent or delay the complications associated with type 2 diabetes (T2D). The benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming increasingly recognized and they now feature prominently in international T2D treatment recommendations and guidelines across the disease continuum. However, despite providing effective glycemic control, weight loss, and a low risk of hypoglycemia, GLP-1RAs are currently underutilized in clinical practice. The long-acting GLP-1RA, semaglutide, is available for once-weekly injection and in a new once-daily oral formulation. Semaglutide is an advantageous choice for the treatment of T2D since it has greater efficacy in reducing glycated hemoglobin and body weight compared with other GLP-1RAs, has demonstrated benefits in reducing major adverse cardiovascular events, and has a favorable profile in special populations (e.g., patients with hepatic impairment or renal impairment). The oral formulation represents a useful option to help improve acceptance and adherence compared with injectable formulations for patients with a preference for oral therapy, and may lead to earlier and broader use of GLP-1RAs in the T2D treatment trajectory. Oral semaglutide should be taken on an empty stomach, which may influence the choice of formulation. As with most GLP-1RAs, initial dose escalation of semaglutide is required for both formulations to mitigate gastrointestinal adverse events. There are also specific dose instructions to follow with oral semaglutide to ensure sufficient gastric absorption. The evidence base surrounding the clinical use of semaglutide is being further expanded with trials investigating effects on diabetic retinopathy, cardiovascular outcomes, and on the common T2D comorbidities of obesity, chronic kidney disease, and non-alcoholic steatohepatitis. These will provide further information about whether the benefits of semaglutide extend to these other indications." @default.
• W3175962993 created "2021-07-05" @default.
• W3175962993 creator A5031742996 @default.
• W3175962993 creator A5064872622 @default.
• W3175962993 date "2021-06-29" @default.
• W3175962993 modified "2023-10-01" @default.
• W3175962993 title "Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide" @default.
• W3175962993 cites W2054088567 @default.
• W3175962993 cites W2099468119 @default.
• W3175962993 cites W2099968605 @default.
• W3175962993 cites W2146264128 @default.
• W3175962993 cites W2150959326 @default.
• W3175962993 cites W2162140339 @default.
• W3175962993 cites W2215535790 @default.
• W3175962993 cites W2311442718 @default.
• W3175962993 cites W2425644022 @default.
• W3175962993 cites W2462710388 @default.
• W3175962993 cites W2493860075 @default.
• W3175962993 cites W2519510391 @default.
• W3175962993 cites W2563047690 @default.
• W3175962993 cites W2592545469 @default.
• W3175962993 cites W2593691145 @default.
• W3175962993 cites W2599180887 @default.
• W3175962993 cites W2599428142 @default.
• W3175962993 cites W2626446274 @default.
• W3175962993 cites W2773698516 @default.
• W3175962993 cites W2774157762 @default.
• W3175962993 cites W2785139619 @default.
• W3175962993 cites W2787255324 @default.
• W3175962993 cites W2795981708 @default.
• W3175962993 cites W2800291410 @default.
• W3175962993 cites W2801613992 @default.
• W3175962993 cites W2808238332 @default.
• W3175962993 cites W2808994737 @default.
• W3175962993 cites W2885588864 @default.
• W3175962993 cites W2885657542 @default.
• W3175962993 cites W2894746763 @default.
• W3175962993 cites W2894993577 @default.
• W3175962993 cites W2899627734 @default.
• W3175962993 cites W2901306081 @default.
• W3175962993 cites W2902989158 @default.
• W3175962993 cites W2908397509 @default.
• W3175962993 cites W2917493414 @default.
• W3175962993 cites W2929744948 @default.
• W3175962993 cites W2944042183 @default.
• W3175962993 cites W2946367335 @default.
• W3175962993 cites W2948230209 @default.
• W3175962993 cites W2948612418 @default.
• W3175962993 cites W2964603908 @default.
• W3175962993 cites W2967100184 @default.
• W3175962993 cites W2971541610 @default.
• W3175962993 cites W2979558564 @default.
• W3175962993 cites W2985391137 @default.
• W3175962993 cites W2996732450 @default.
• W3175962993 cites W3001370696 @default.
• W3175962993 cites W3006890954 @default.
• W3175962993 cites W3014018229 @default.
• W3175962993 cites W3017299275 @default.
• W3175962993 cites W3028216699 @default.
• W3175962993 cites W3044996075 @default.
• W3175962993 cites W3102426258 @default.
• W3175962993 cites W3106528346 @default.
• W3175962993 cites W3127371223 @default.
• W3175962993 cites W3129305070 @default.
• W3175962993 cites W3133746780 @default.
• W3175962993 cites W3138431202 @default.
• W3175962993 cites W4206445899 @default.
• W3175962993 cites W4246340431 @default.
• W3175962993 cites W4253996779 @default.
• W3175962993 doi "https://doi.org/10.3389/fendo.2021.645507" @default.
• W3175962993 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8276717" @default.
• W3175962993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34267725" @default.
• W3175962993 hasPublicationYear "2021" @default.
• W3175962993 type Work @default.
• W3175962993 sameAs 3175962993 @default.
• W3175962993 citedByCount "18" @default.
• W3175962993 countsByYear W31759629932021 @default.
• W3175962993 countsByYear W31759629932022 @default.
• W3175962993 countsByYear W31759629932023 @default.
• W3175962993 crossrefType "journal-article" @default.
• W3175962993 hasAuthorship W3175962993A5031742996 @default.
• W3175962993 hasAuthorship W3175962993A5064872622 @default.
• W3175962993 hasBestOaLocation W31759629931 @default.
• W3175962993 hasConcept C126322002 @default.
• W3175962993 hasConcept C134018914 @default.
• W3175962993 hasConcept C177713679 @default.
• W3175962993 hasConcept C197934379 @default.
• W3175962993 hasConcept C2777180221 @default.
• W3175962993 hasConcept C2777538456 @default.
• W3175962993 hasConcept C2780473172 @default.
• W3175962993 hasConcept C2780668416 @default.
• W3175962993 hasConcept C2781308992 @default.
• W3175962993 hasConcept C2909862629 @default.
• W3175962993 hasConcept C511355011 @default.
• W3175962993 hasConcept C544821477 @default.
• W3175962993 hasConcept C555293320 @default.
• W3175962993 hasConcept C71924100 @default.
• W3175962993 hasConceptScore W3175962993C126322002 @default.
• W3175962993 hasConceptScore W3175962993C134018914 @default.
• W3175962993 hasConceptScore W3175962993C177713679 @default.

• next